SCHEMBL1056142

SCHEMBL1056142

CC(C)(C)OC(=O)n1ccc2ccc(C=O)cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.51
PIK3CD O00329 2/20 0.38
ABL1 P00519 2/20 0.38
EGFR P00533 2/20 0.38
HCK P08631 2/20 0.38
SRC P12931 2/20 0.38
KDR P35968 2/20 0.38
PIK3CA P42336 2/20 0.38
PIK3CB P42338 2/20 0.38
MTOR P42345 2/20 0.38
PIK3CG P48736 2/20 0.38
EPHB4 P54760 2/20 0.38
PRKDC P78527 2/20 0.38
PI4KB Q9UBF8 2/20 0.38
BUB1 O43683 1/20 0.38
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
NR1H2 P55055 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853981 1.00 CYP2A6 (0.51) CYP2A6PIK3CDABL1EGFRHCK
SCHEMBL1056190 0.89 CYP2A6 (0.51) CYP2A6PIK3CDABL1EGFRHCK
SCHEMBL1058737 0.88 PIK3CD (0.37) CYP2A6PIK3CDABL1EGFRHCK
SCHEMBL1058264 0.83 ALDH1A1 (0.36) CYP2A6PIK3CDABL1EGFRHCK
SCHEMBL1058266 0.83 ALDH1A1 (0.36) CYP2A6PIK3CDABL1EGFRHCK
SCHEMBL1056549 0.82 TTR (0.46) NR1H2KDM4EALDH1A1ACHEHDAC1
SCHEMBL1056550 0.82 TTR (0.46) NR1H2KDM4EALDH1A1ACHEHDAC1
SCHEMBL29820909 0.81 HTR6 (0.46) PIK3CDABL1EGFRHCKSRC
SCHEMBL1373109 0.81 HTR6 (0.46) PIK3CDABL1EGFRHCKSRC
SCHEMBL10193516 0.81 BUB1 (0.40) PIK3CDABL1EGFRHCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2025-04-17 US disclosed
CN-119790053-A Sulfonamide derivatives as cyclin dependent kinase 2 inhibitors 霖康疗法公司 2025-04-08 CN disclosed
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2025-01-14 US disclosed
WO-2023240024-A1 SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
US-20230131535-A1 ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-04-27 US disclosed
US-20230116403-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS EVOTEC INTERNATIONAL GMBH (DE) 2023-04-13 US disclosed
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2023-01-05 US disclosed
US-20080103137-A1 Deazapurines and uses thereof EISAI CO., LTD. 2008-05-01 US disclosed
US-7314936-B2 Deazapurines and uses thereof EISAI CO., LTD. (JP) 2008-01-01 US disclosed
EP-1707566-A1 Deazapurines and uses thereof Eisai Co., Ltd. (JP) 2006-10-04 EP disclosed
EP-1474425-B1 DEAZAPURINES AND USES THEREOF EISAI CO LTD (JP) 2006-05-24 EP disclosed
US-20050154039-A1 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine IPSEN PHARMA S.A.S. (FR) 2005-07-14 US disclosed
US-20050124649-A1 Deazapurines and uses thereof EISAI CO., LTD (JP) 2005-06-09 US disclosed
EP-1465880-A1 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE AS MEDICINE SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-10-13 EP disclosed
US-20040186127-A1 Novel deazapurines and uses thereof EISAI CO., LTD. (JP) 2004-09-23 US disclosed
WO-2004063336-A2 USES OF DEAZAPURINES FOR THE TREATMENT OF REPERFUSION INJURIES, OSTEOPOROSIS AND/OR BONE METASTASIS EISAI CO. LTD. (JP) 2004-07-29 WO disclosed
WO-2003045926-A1 5-SULPHANYL-4H-1,2,4-TRIAZOLE DERIVATIVES AND THEIR USE AS MEDICINE SOCIETE DE CONSEILS DE RECHERCHE ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT CYP2A6 2433/4885PIK3CD 2669/4885ABL1 795/4885
US-20050124649-A1 Deazapurines and uses thereof TPMT, CD38, CD2 CYP2A6 3228/4885PIK3CD 2922/4885ABL1 1396/4885
US-20050154039-A1 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine SSTR3, SSTR1, SSTR5 CYP2A6 1540/4885PIK3CD 1452/4885ABL1 1352/4885
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT CYP2A6 2433/4885PIK3CD 2669/4885ABL1 795/4885
US-20230116403-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT CYP2A6 2433/4885PIK3CD 2669/4885ABL1 795/4885
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT CYP2A6 2433/4885PIK3CD 2669/4885ABL1 795/4885
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT CYP2A6 2433/4885PIK3CD 2669/4885ABL1 795/4885
US-20230131535-A1 ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNK3 CYP2A6 1161/4885PIK3CD 1221/4885ABL1 279/4885
US-20080103137-A1 Deazapurines and uses thereof TPMT, TYMP, ENTPD5 CYP2A6 789/4885PIK3CD 2770/4885ABL1 1375/4885
US-20040186127-A1 Novel deazapurines and uses thereof TPMT, ENTPD5, MTAP CYP2A6 1543/4885PIK3CD 2205/4885ABL1 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.